Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study
| Autor: | Claus Wolff-Menzler, Antonie Wimmer, Kerstin Olbrich, Adrian Wilk, Jörg Mahlich |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent 030204 cardiovascular system & hematology 030226 pharmacology & pharmacy Drug Costs Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Recurrence Germany Internal medicine Humans Medicine Pharmacology (medical) Original Research Article Young adult Medical prescription Aged Retrospective Studies business.industry Retrospective cohort study Health Care Costs General Medicine Middle Aged medicine.disease Hospitalization Schizophrenia Delayed-Action Preparations Cohort Ambulatory Female business Antipsychotic Agents Cohort study |
| Zdroj: | Clinical Drug Investigation |
| ISSN: | 1179-1918 1173-2563 |
| Popis: | Background Long-acting injectable (LAI) antipsychotics can reduce relapse, hospitalization, and costs in patients with schizophrenia. However, real-world evidence assessing the impact of treatment with LAIs in Germany is limited. Objective To provide updated evidence on the impact of LAI initiation on hospitalization rates and therapy costs. Methods Using a mirror-image design, claims data of 850 German patients with schizophrenia who initiated treatment with LAIs during 2013–2015 was retrospectively analyzed. For the included patients, costs and resource utilization were compared for the 12 months before the index date (first initiation of LAI) and the 12 months after the index date. Annual treatment costs, hospitalization rates, ambulatory visits, sick leaves and medical aids were assessed. Two models were used to evaluate hospitalization and its costs. In model 1, hospitalization during the index date (first LAI prescription in 2013–2015) was allocated to the “pre-” time interval, while in model 2 it was neither attributed to the pre- nor to the post-index date. Regression analysis was performed to identify patients who benefited the most in terms of cost reduction from LAI initiation. Results Medication costs were significantly higher post-switching to LAI compared with pre-switching period (€3832 vs €799; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink